| Ms Joy A Mcelroy, MD | |
|
77-311 Sunset Dr, Kailua Kona, HI 96740-9754 | |
| (808) 329-6355 | |
| (808) 326-1549 |
| Full Name | Ms Joy A Mcelroy |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 38 Years |
| Location | 77-311 Sunset Dr, Kailua Kona, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336211952 | NPI | - | NPPES |
| B90023 | Other | HMSA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 8319 (Hawaii) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Joy A Mcelroy M D Inc | 5698744936 | 3 |
News Archive
Quest Diagnostics' healthcare information (IT) technology subsidiary MedPlus and the American Medical Association (AMA), the nation's largest physician organization, today announced they are partnering to expand the adoption of health information technology by offering Care360™ EHR, a web-based electronic health record, on the AMA's new online platform for physicians.
Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.
Researchers have been able to confirm most but not all of the results of a high-profile study that brought new hope to diabetes patients. This study provides a boost for efforts to reverse type-1 diabetes in recently diagnosed patients but not for efforts to grow new islets from spleens.
The Food and Drug Administration (FDA) ensures that high-risk medical devices, such as implantable cardioverter-defibrillators and pacemakers, are safe and effective through its premarket approval (PMA) pathway, during which manufacturers must collect preclinical and clinical data before the device is approved.
› Verified 5 days ago
| Entity Name | Joy A Mcelroy M D Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770610875 PECOS PAC ID: 5698744936 Enrollment ID: O20041001001066 |
News Archive
Quest Diagnostics' healthcare information (IT) technology subsidiary MedPlus and the American Medical Association (AMA), the nation's largest physician organization, today announced they are partnering to expand the adoption of health information technology by offering Care360™ EHR, a web-based electronic health record, on the AMA's new online platform for physicians.
Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.
Researchers have been able to confirm most but not all of the results of a high-profile study that brought new hope to diabetes patients. This study provides a boost for efforts to reverse type-1 diabetes in recently diagnosed patients but not for efforts to grow new islets from spleens.
The Food and Drug Administration (FDA) ensures that high-risk medical devices, such as implantable cardioverter-defibrillators and pacemakers, are safe and effective through its premarket approval (PMA) pathway, during which manufacturers must collect preclinical and clinical data before the device is approved.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Joy A Mcelroy, MD Po Box 2508, Kailua Kona, HI 96745-2508 Ph: (808) 329-6355 | Ms Joy A Mcelroy, MD 77-311 Sunset Dr, Kailua Kona, HI 96740-9754 Ph: (808) 329-6355 |
News Archive
Quest Diagnostics' healthcare information (IT) technology subsidiary MedPlus and the American Medical Association (AMA), the nation's largest physician organization, today announced they are partnering to expand the adoption of health information technology by offering Care360™ EHR, a web-based electronic health record, on the AMA's new online platform for physicians.
Researchers at the University of Michigan Comprehensive Cancer Center have developed a new drug called AT-406 with potential to treat multiple types of cancer.
Researchers have been able to confirm most but not all of the results of a high-profile study that brought new hope to diabetes patients. This study provides a boost for efforts to reverse type-1 diabetes in recently diagnosed patients but not for efforts to grow new islets from spleens.
The Food and Drug Administration (FDA) ensures that high-risk medical devices, such as implantable cardioverter-defibrillators and pacemakers, are safe and effective through its premarket approval (PMA) pathway, during which manufacturers must collect preclinical and clinical data before the device is approved.
› Verified 5 days ago
Dr. Parwathi V. Paniker, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 74-517 Honokohau St, Kailua Kona, HI 96740 Phone: 808-334-4400 | |
Dr. Monica M Scheel, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 73-5618 Maiau St, Suite A204, Kailua Kona, HI 96740 Phone: 808-329-1146 Fax: 808-326-2871 |